Taxotere And Its Relation To Permanent Hair Loss

Oct 19, 2016 by

Drug manufacturer Sanofi Aventis has recently been barraged by lawsuits in relation to its drug taxotere. Studies have shown a relation between taxotere and alopecia induced by chemotherapy drug. Hair loss is one of the usual side effects of chemotherapy but patients expect their hair to grow back in a period of 3 to 6 months. But instead of growth, patients reportedly suffered from permanent and irreversible hair loss.

Taxotere is designed to treat certain cancers such as breast cancers, prostate cancer, and advanced stomach cancer. The drug helps prevent cancer cells from developing in the patient’s body. Some patients alleged that the opposite happened causing them to lose their hair. In a study published in the Annals of Oncology, it was revealed that docetaxel is associated with an increased risk of permanent alopecia. The study involved 20 female patients who were treated for breast cancer, treated taxotere, and developed permanent alopecia.

Several studies have been conducted in order to determine the relation between taxotere and permanent hair loss. The GEICAM 9805, funded by Sanofi, came up with the conclusion that 9.2 percent of patients experienced hair loss that lasted for more than 10 years based from data presented in the Ami Dodson lawsuit. A study conducted by Dr. Scot Sedlacek, on the other hand, revealed that taxotere could cause 6 percent of women to suffer permanent alopecia.

In recent studies, Taxotere showed better performance in extending the survival of breast cancer patients. But studies have also revealed a distressing side effect for patients and that is permanent hair loss. For this reason, the manufacturer of the drug Sanofi faces a growing number of lawsuits filed by women for their failure to warn them about the severity and permanence of hair loss. According to them, if they were informed about the potential of hair loss, they would have opted for another treatment.

Related Posts

Tags

Share This

Leave a Reply

Your email address will not be published. Required fields are marked *